Moderna Non Operating Income Net Other vs Research Development Analysis
MRNA Stock | USD 166.61 2.60 1.59% |
Moderna financial indicator trend analysis is infinitely more than just investigating Moderna recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moderna is a good investment. Please check the relationship between Moderna Non Operating Income Net Other and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
Non Operating Income Net Other vs Research Development
Non Operating Income Net Other vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moderna Non Operating Income Net Other account and Research Development. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Moderna's Non Operating Income Net Other and Research Development is 0.88. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Research Development in the same time period over historical financial statements of Moderna, assuming nothing else is changed. The correlation between historical values of Moderna's Non Operating Income Net Other and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of Moderna are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Non Operating Income Net Other i.e., Moderna's Non Operating Income Net Other and Research Development go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Non Operating Income Net Other
Research Development
Most indicators from Moderna's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 1.2 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.19.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 18M | 200M | 405M | 425.3M | Net Interest Income | 18M | 200M | 363M | 381.2M |
Moderna fundamental ratios Correlations
Click cells to compare fundamentals
Moderna Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Moderna fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.6B | 7.3B | 24.7B | 25.9B | 18.4B | 19.3B | |
Total Current Liabilities | 143.1M | 4.4B | 9.1B | 4.9B | 3.0B | 2.4B | |
Total Stockholder Equity | 1.2B | 2.6B | 14.1B | 19.1B | 13.9B | 14.5B | |
Other Liab | 139.1M | 179.3M | 691M | 808M | 929.2M | 975.7M | |
Net Tangible Assets | 1.2B | 2.6B | 14.1B | 19.1B | 22.0B | 23.1B | |
Retained Earnings | (1.5B) | (2.2B) | 10.0B | 18.3B | 13.6B | 14.3B | |
Accounts Payable | 7.1M | 18.4M | 302M | 487M | 520M | 546M | |
Cash | 235.9M | 2.6B | 6.8B | 3.2B | 2.9B | 1.8B | |
Net Receivables | 16.3M | 1.4B | 3.3B | 1.4B | 1.1B | 886.7M | |
Other Current Assets | 887.9M | (405.6M) | 55M | 1.2B | 88M | 83.6M | |
Total Liab | 414.6M | 4.8B | 10.5B | 6.7B | 4.6B | 3.1B | |
Total Current Assets | 1.3B | 6.3B | 17.6B | 13.4B | 10.3B | 5.8B | |
Common Stock | 33K | 34K | 40K | (857M) | (771.3M) | (732.7M) | |
Other Current Liab | 5.1M | 33.7M | 2.4B | 2.2B | 1.9B | 2.0B | |
Common Stock Shares Outstanding | 330.8M | 381.3M | 431M | 416M | 382M | 346.5M | |
Short Long Term Debt Total | 132.4M | 207.3M | 916M | 1.2B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 287.9M | 387.1M | 1.4B | 2.1B | 2.7B | 2.8B | |
Current Deferred Revenue | 63.3M | 3.9B | 6.3B | 2.0B | 568M | 539.6M | |
Net Debt | (103.5M) | (2.4B) | (5.9B) | (2.0B) | (1.7B) | (1.7B) | |
Non Current Assets Total | 326.4M | 1.0B | 7.1B | 12.4B | 8.1B | 4.1B | |
Non Currrent Assets Other | (121.5M) | 12.9M | 46M | 988M | 523M | 549.2M | |
Other Assets | 12.7M | 742.0M | 7.4B | 1.9B | 2.2B | 1.6B | |
Cash And Short Term Investments | 1.3B | 5.2B | 17.6B | 9.9B | 8.6B | 6.3B | |
Short Term Investments | 867.1M | 2.0B | 3.9B | 6.7B | 5.7B | 3.0B | |
Liabilities And Stockholders Equity | 1.6B | 7.3B | 24.7B | 25.9B | 18.4B | 11.3B | |
Non Current Liabilities Total | 271.5M | 386.6M | 1.4B | 1.8B | 1.6B | 868.0M | |
Capital Surpluse | 2.7B | 4.8B | 4.2B | 1.2B | 1.3B | 2.4B | |
Capital Lease Obligations | 132.4M | 207.3M | 916M | 1.0B | 1.2B | 1.3B | |
Other Stockholder Equity | 2.7B | 4.8B | 4.2B | 1.2B | 371M | 352.5M | |
Long Term Investments | 160.0M | 638.8M | 6.8B | 8.3B | 4.7B | 2.9B | |
Accumulated Other Comprehensive Income | 1.8M | 3.0M | (24M) | (370M) | (123M) | (116.9M) | |
Non Current Liabilities Other | 138K | 386.6M | 1.4B | 135M | 256M | 299.3M | |
Short Term Debt | 67.7M | 469.6M | 211M | 196M | 25M | 23.8M | |
Property Plant Equipment | 287.9M | 387.1M | 1.4B | 2.1B | 2.5B | 2.6B | |
Net Invested Capital | 1.2B | 2.6B | 14.1B | 19.1B | 13.9B | 8.1B | |
Property Plant And Equipment Gross | 287.9M | 387.1M | 1.7B | 2.1B | 3.1B | 3.2B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (15.59) | Revenue Per Share 13.525 | Quarterly Revenue Growth (0.91) | Return On Assets (0.16) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.